GlassScriptPhysician profile
Roger H Karlin
NPI 1700894177
$7,428.74
in general payments reported to CMS, 2019-2025
37 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $1,092 · 2021: $1,222 · 2022: $1,235 · 2023: $947 · 2024: $733 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,513.66 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,119.39 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $758.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $603.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $596.06 | 2020-2025 | |
| Pfizer INC. | $474.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $388.74 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $268.26 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $176.11 | 2019-2022 | |
| Allergan, INC. | $168.58 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $131.74 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $126.32 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.46 | 2022-2025 | Xifaxan |
| Arbor Pharmaceuticals, INC. | $107.00 | 2019-2021 | |
| Amgen INC. | $89.64 | 2021-2023 | Repatha, Otezla |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $85.49 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $82.64 | 2019-2021 | |
| Eisai INC. | $75.71 | 2019-2022 | |
| Esperion Therapeutics, INC. | $68.60 | 2024-2025 | Nexletol |
| Shire North American Group INC | $62.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $59.13 | 2022 | |
| Antares Pharma, INC. | $42.50 | 2020 | |
| Adlon Therapeutics L.P. | $33.62 | 2020-2021 | |
| Optinose US, INC. | $31.66 | 2020 | |
| Aimmune Therapeutics, INC. | $26.03 | 2021 | |
| Azurity Pharmaceuticals, INC. | $21.72 | 2023 | Edarbi |
| Jazz Pharmaceuticals INC. | $21.43 | 2020 | |
| Verona Pharma, INC. | $20.96 | 2025 | Ohtuvayre |
| Vivus LLC | $20.35 | 2019 | |
| Medicure Pharma INC. | $20.24 | 2021 | |
| Genentech USA, INC. | $19.28 | 2019 | |
| Astellas Pharma US INC | $18.98 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.12 | 2022 | |
| Exact Sciences Corporation | $15.43 | 2025 | The Cologuard Plus Collection Kit |
| Alk-Abello, INC | $15.00 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $12.03 | 2019 | |
| Almatica Pharma LLC | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Karlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.